Welcome to ProbeChem!Global Supplier of Chemical Probes, Inhibitors & Agonists.
Chemical Structure : KY-273
Catalog No.: PC-22032Not For Human Use, Lab Use Only.
KY-273 (KY273) is a potent, specific CDK8/19 inhibitor with IC50 of 29.1 and 44.7 nM respectively, promotes osteoblast differentiation and has cortical-bone-selective osteogenic effects.
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
KY-273 (KY273) is a potent, specific CDK8/19 inhibitor with IC50 of 29.1 and 44.7 nM respectively, promotes osteoblast differentiation and has cortical-bone-selective osteogenic effects.
KY-273 displays little effect on CDK2, CDK3, CDK4, CDK5 and CDK6 even at 1000 nM, also has no effect on CDK7 and CDK9 activities.
KY-273 promotes osteoblast differentiation with an increase in alkaline phosphatase (ALP) activity.
KY-273 (0.1-10 uM) concentration- and time-dependently increased ALP activities in ST2 Cells, enhances mRNA expression of Type I collagen.
KY-273 (10 mg/kg/d, p.o. 6 Weeks) increases metaphyseal and diaphyseal Ct.BV, Ct.BMC, and BSPs without affecting medullary volume (Med.V), but doesnot affect Tb.BV and Tb.BMC, in ovaries-intact and ovariectomized rats.
KY-273 increases bone formation rate/bone surface at the periosteal but not the endocortical side, in ovaries-intact and ovariectomized rats.
| M.Wt | 401.46 | |
| Formula | C22H27NO6 | |
| Appearance | Solid | |
| Storage |
|
|
| Solubility |
10 mM in DMSO |
|
1. Megumi Yamamoto, et al. Biol Pharm Bull. 2024;47(3):669-679.
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright
